Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • P886: AFRICAN AMERICAN PATIENT...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
P886: AFRICAN AMERICAN PATIENTS WITH SMOLDERING MULTIPLE MYELOMA MAY HAVE A LOWER RISK OF PROGRESSION COMPARED TO WHITE PATIENTS

P886: AFRICAN AMERICAN PATIENTS WITH SMOLDERING MULTIPLE MYELOMA MAY HAVE A LOWER RISK OF PROGRESSION COMPARED TO WHITE PATIENTS

Bibliographic Details
Main Authors: T. Akhlaghi, K. Maclachlan, N. Korde, S. Mailankody, A. Lesokhin, H. Hassoun, S. X. Lu, D. Patel, U. Shah, C. Tan, A. Derkach, O. Lahoud, H. J. Landau, G. L. Shah, M. Scordo, D. J. Chung, S. A. Giralt, S. Z. Usmani, O. Landgren, M. Hultcrantz
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/01.HS9.0000846420.96485.de
  • Holdings
  • Description
  • Similar Items
  • Staff View
Description
ISSN:2572-9241

Similar Items

  • S177: EVALUATING SERUM FREE LIGHT CHAIN RATIO AS A BIOMARKER FOR MULTIPLE MYELOMA
    by: T. Akhlaghi, et al.
    Published: (2022-06-01)
  • Evaluating serum free light chain ratio as a biomarker in multiple myeloma
    by: Theresia Akhlaghi, et al.
    Published: (2024-10-01)
  • P962: COMMERCIAL TECLISTAMAB IN ANTI-BCMA THERAPY EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS: THE MSKCC EXPERIENCE.
    by: Ross Firestone, et al.
    Published: (2023-08-01)
  • Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
    by: Carlyn Rose Tan, et al.
    Published: (2023-07-01)
  • Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials
    by: Elisabet E Manasanch, et al.
    Published: (2014-12-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs